307 related articles for article (PubMed ID: 35739428)
21. A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.
Mohebbi A; Shahriyary F; Farrokhi V; Bandar B; Saki N
Leuk Res; 2024 Jun; 141():107505. PubMed ID: 38692232
[TBL] [Abstract][Full Text] [Related]
22. Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Chen N; Pan J; Zhou Y; Mao L; Lou Y; Qian J; Xu G; Wei J; Zhou D; Shou L; Huang L; Yan M; Zeng H; Fan C; Wu G; Feng W; Tong H; Jin J; Wang H
Br J Haematol; 2024 Mar; 204(3):861-870. PubMed ID: 37939390
[TBL] [Abstract][Full Text] [Related]
23. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.
Usuki K; Sakura T; Kobayashi Y; Miyamoto T; Iida H; Morita S; Bahceci E; Kaneko M; Kusano M; Yamada S; Takeshita S; Miyawaki S; Naoe T
Cancer Sci; 2018 Oct; 109(10):3235-3244. PubMed ID: 30039554
[TBL] [Abstract][Full Text] [Related]
24. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
[TBL] [Abstract][Full Text] [Related]
25. [Gilteritinib for pediatric FLT3 internal tandem duplication-positive recurrent acute myeloid leukemia].
Fukuoka K; Tsumura Y; Noguchi J; Sugawa M; Takaki T; Hiraki T; Inoue K; Mitani Y; Tomita O; Oshima K; Yanagi M; Isobe K; Mori M; Arakawa Y; Koh K
Rinsho Ketsueki; 2020; 61(4):322-326. PubMed ID: 32378574
[TBL] [Abstract][Full Text] [Related]
26. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.
Daver N; Venugopal S; Ravandi F
Blood Cancer J; 2021 May; 11(5):104. PubMed ID: 34045454
[TBL] [Abstract][Full Text] [Related]
27. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Perl AE; Larson RA; Podoltsev NA; Strickland S; Wang ES; Atallah E; Schiller GJ; Martinelli G; Neubauer A; Sierra J; Montesinos P; Récher C; Yoon SS; Hosono N; Onozawa M; Chiba S; Kim HJ; Hasabou N; Lu Q; Tiu R; Levis MJ
Blood; 2022 Jun; 139(23):3366-3375. PubMed ID: 35081255
[TBL] [Abstract][Full Text] [Related]
28. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
[TBL] [Abstract][Full Text] [Related]
29. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
[TBL] [Abstract][Full Text] [Related]
30. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
31. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.
Arrigo G; D'Ardìa S; Audisio E; Cerrano M; Freilone R; Giai V; Secreto C; Urbino I; Frairia C
Acta Haematol; 2022; 145(5):566-570. PubMed ID: 35580565
[TBL] [Abstract][Full Text] [Related]
32. [Successful treatment with gilteritinib for relapsed acute myeloid leukemia with FLT3-N676K mutation].
Miyajima T; Harada S; Ogasawara R; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Chi S; Minami Y; Kondo T
Rinsho Ketsueki; 2022; 63(1):51-54. PubMed ID: 35135952
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo D; Tinajero J; Li S; Palmer J; Pourhassan H; Aribi A; Nakamura R; Stein A; Marcucci G; Salhotra A; Sandhu K; Pullarkat V; Ball B; Koller P
Leuk Lymphoma; 2024 Mar; 65(3):372-377. PubMed ID: 38164785
[TBL] [Abstract][Full Text] [Related]
34. A novel approach for relapsed/refractory FLT3
Li KX; Wu HY; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Yang DH; Huang YX
Mol Cancer; 2022 Mar; 21(1):66. PubMed ID: 35246156
[TBL] [Abstract][Full Text] [Related]
35. Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
Pratz KW; Cherry M; Altman JK; Cooper BW; Podoltsev NA; Cruz JC; Lin TL; Schiller GJ; Jurcic JG; Asch A; Wu R; Hill JE; Gill SC; James AJ; Rich ES; Hasabou N; Perl AE; Levis MJ
J Clin Oncol; 2023 Sep; 41(26):4236-4246. PubMed ID: 37379495
[TBL] [Abstract][Full Text] [Related]
36. BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors.
Buelow DR; Bhatnagar B; Orwick SJ; Jeon JY; Eisenmann ED; Stromatt JC; Pabla NS; Blachly JS; Baker SD; Blaser BW
Blood Adv; 2022 Sep; 6(17):5049-5060. PubMed ID: 35797240
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
38. A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.
Perrone S; Ortu La Barbera E; Viola F; Cipollone E; Scerpa MC; Siniscalchi R; Ottone T; Voso MT; Cimino G
Chemotherapy; 2021; 66(4):134-138. PubMed ID: 34515081
[TBL] [Abstract][Full Text] [Related]
39. Outcome of Relapsed or Refractory
Bertoli S; Dumas PY; Bérard E; Largeaud L; Bidet A; Delabesse E; Tavitian S; Gadaud N; Leguay T; Leroy H; Rieu JB; Vial JP; Vergez F; Lechevalier N; Luquet I; Klein E; Sarry A; Grande AC; Récher C; Pigneux A
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218221
[TBL] [Abstract][Full Text] [Related]
40. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY; Raffoux E; Bérard E; Bertoli S; Hospital MA; Heiblig M; Desbrosses Y; Bonmati C; Pautas C; Lambert J; Orvain C; Banos A; Pasquier F; Peterlin P; Marchand T; Uzunov M; Frayfer J; Turlure P; Cluzeau T; Jourdan E; Himberlin C; Tavernier E; Villate A; Haiat S; Chretien ML; Carre M; Chantepie S; Vaida I; Wemeau M; Chebrek S; Guillerm G; Guièze R; Debarri H; Gehlkopf E; Laribi K; Marcais A; Santagostino A; Béné MC; Mineur A; Pigneux A; Dombret H; Récher C
Leukemia; 2023 Jan; 37(1):91-101. PubMed ID: 36376378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]